MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13014-021-01795-5

Медицинская библиотека · Radiation oncology (London, England) · 2021

A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma.

Lin Charles, Ballah Trishna, Nottage Michelle, Hay Karen, Chua Benjamin, Kenny Lizbeth, Thomas Paul, Teng Michele, Keller Jacqui, Le Trang, Edmunds Jennifer, Hughes Brett

Клиническое исследование II фазыСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Patients with unresectable advanced cutaneous squamous cell carcinoma (cSCC) are generally treated with palliative intent. Immune checkpoint blockade has significant activity in the palliative setting in patients with recurrent or metastatic cSCC. This single arm phase 2 prospective study aims to investigate the combination of curative intent chemoradiation and durvalumab (anti-PD-L1 checkpoint inhibitor) for this patient cohort.

METHODS

Patients with unresectable locally and or regionally advanced pathologically confirmed cSCC (stage III-IVa) deemed fit for CRIO by consensus of the Multidisciplinary meeting will be eligible. In the first stage of a two-stage minimax design, we aim to recruit a total of 15 patients. If fewer than 7 patients achieved a complete response in the first stage, we will conclude the treatment is not more effective than standard treatment. The co-primary endpoints of CRIO are the safety of treatment (acute and late toxicities) and the rate of complete response. Secondary endpoints would include overall survival, progression free survival, and locoregional control. Translational research endpoints including biomarkers (CD73, CD39, PD-1, PD-L1) will also be explored utilising multiplex immunohistochemistry on tumour biopsy samples obtained prior to commencing treatment and during treatment (week 2). In addition, the utility of CXCR-4 PET/CT scan will be explored.

DISCUSSION: CRIO is a novel trial evaluating the combination of curative intent chemoradiotherapy with concurrent and adjuvant durvalumab for patients with unresectable stage III-IVa cSCC.

TRIAL REGISTRATION: Trial registered with the Australian New Zealand Clinical Trial Registry (ACTRN12618001573246).

Для цитирования: Lin Charles, Ballah Trishna, Nottage Michelle, Hay Karen, Chua Benjamin, Kenny Lizbeth, Thomas Paul, Teng Michele, Keller Jacqui, Le Trang, Edmunds Jennifer, Hughes Brett. A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma.. Radiation oncology (London, England). 2021. DOI: 10.1186/s13014-021-01795-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.